MX349947B - Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada. - Google Patents

Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada.

Info

Publication number
MX349947B
MX349947B MX2014001306A MX2014001306A MX349947B MX 349947 B MX349947 B MX 349947B MX 2014001306 A MX2014001306 A MX 2014001306A MX 2014001306 A MX2014001306 A MX 2014001306A MX 349947 B MX349947 B MX 349947B
Authority
MX
Mexico
Prior art keywords
methods
clostridial toxin
treating chronic
modified clostridial
neurogenic inflammation
Prior art date
Application number
MX2014001306A
Other languages
English (en)
Spanish (es)
Inventor
Gaxiola Meza Gustavo
Aguilar Enriquez Ivan
Paz Padilla Gilberto
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX349947B publication Critical patent/MX349947B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2014001306A 2009-08-26 2010-08-10 Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada. MX349947B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/548,073 US8147848B2 (en) 2009-08-26 2009-08-26 Method for treating premature ejaculation with a botulinum neurotoxin
PCT/US2010/044959 WO2011028371A1 (en) 2009-08-26 2010-08-10 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin

Publications (1)

Publication Number Publication Date
MX349947B true MX349947B (es) 2017-08-22

Family

ID=43127150

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014001306A MX349947B (es) 2009-08-26 2010-08-10 Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada.
MX2012002378A MX2012002378A (es) 2009-08-26 2010-08-10 Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012002378A MX2012002378A (es) 2009-08-26 2010-08-10 Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada.

Country Status (18)

Country Link
US (8) US8147848B2 (enExample)
EP (2) EP2470202B1 (enExample)
JP (2) JP5766699B2 (enExample)
KR (1) KR101612988B1 (enExample)
CN (2) CN103816530B (enExample)
AU (2) AU2010289969B2 (enExample)
BR (1) BR112012004246A2 (enExample)
CA (1) CA2772372C (enExample)
CY (1) CY1114792T1 (enExample)
DK (2) DK2470202T3 (enExample)
ES (2) ES2564677T3 (enExample)
IN (1) IN2012DN02210A (enExample)
MX (2) MX349947B (enExample)
PL (1) PL2470202T3 (enExample)
PT (1) PT2470202E (enExample)
RU (1) RU2568844C2 (enExample)
SI (1) SI2470202T1 (enExample)
WO (1) WO2011028371A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US20120251518A1 (en) * 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20130066148A1 (en) * 2011-09-12 2013-03-14 Kang Seon Cho Method of augmenting glans
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
US9764010B2 (en) * 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin
DK3188706T3 (da) * 2014-09-02 2020-01-20 American Silver Llc Botulinumtoksin og kolloide sølvpartikler
RU2565104C1 (ru) * 2014-10-24 2015-10-20 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ лечения преждевременной эякуляции
AU2018270092C1 (en) * 2017-05-18 2026-01-08 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia
WO2018220232A1 (en) * 2017-06-02 2018-12-06 Universite De Versailles-St Quentin En Yvelines Pharmaceutical combination product comprising botulinum toxin for the treatment of erectile dysfunction
US12102556B2 (en) 2022-05-31 2024-10-01 Max Azevedo System and method for fallopian birth control
US12337014B1 (en) 2024-06-17 2025-06-24 Enrico Guarino Intracavernosal gel infusion system with neurotoxin modulation for erectile function
WO2026118698A1 (en) * 2024-12-03 2026-06-11 Obigen Pharma, Inc. Novel use of clostridium botulinum toxin type a for treatment of glabellar lines

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5427291A (en) 1993-09-21 1995-06-27 Smith; David S. Ski carrier and method employing same
DE69434535T2 (de) 1993-12-28 2006-07-20 Allergan, Inc., Irvine Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
CN1123680A (zh) * 1994-11-18 1996-06-05 吕建京 一种对于肺脾肾虚有良好功效的保健品及其制造方法
ATE320815T1 (de) 1997-07-15 2006-04-15 Univ Colorado Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
CN1146866C (zh) * 1998-11-17 2004-04-21 阿尔卑斯电气株式会社 浮起式磁头的冠顶形成方法及冠顶形成装置
FR2793689B1 (fr) 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
RU2180591C2 (ru) * 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
NZ528935A (en) 2001-03-16 2004-10-29 Dmi Biosciences Inc Method of delaying ejaculation
CZ20032644A3 (en) 2001-03-29 2004-06-16 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
DK1474143T3 (da) * 2002-01-25 2009-01-26 Modular Properties Ltd Fremgangsmåder og sammensætninger til bahandling af mandlig erektil dysfunktion
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
TW200418838A (en) * 2002-09-18 2004-10-01 Bristol Myers Squibb Co Compounds for the treatment of premature ejaculation
WO2005072433A2 (en) * 2004-01-26 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Toxin induced sympathectomy
US20060100584A1 (en) 2004-08-10 2006-05-11 Orest Olejnik Needleless microprotrusion elastoplast system
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
CN1682810A (zh) * 2005-02-22 2005-10-19 黄资源 一种治疗前列腺疾病的前列外敷散
KR20070110402A (ko) 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
WO2007059528A2 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US7445783B2 (en) 2006-10-30 2008-11-04 Cappellos, Inc. Topical and transdermal treatments using urea formulations
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
US20090005319A1 (en) * 2007-07-01 2009-01-01 Barone Jr Frank V Topical compositions for delaying ejaculation and methods of using the same
US20090093547A1 (en) * 2007-10-09 2009-04-09 Sciele Pharma, Inc. Compositions and Methods for Treating Premature Ejaculation
CA2703370A1 (en) 2007-10-23 2009-04-30 Allergan, Inc. Methods of treating urogenital-neurological disorders using modified clostridial toxins
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US9049616B2 (en) 2012-03-29 2015-06-02 Broadcom Corporation Session recovery after network coordinator or AP restart for single user, multiple user, multiple access, and/or MIMO wireless communications
US9764010B2 (en) 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin

Also Published As

Publication number Publication date
CN102802663B (zh) 2014-03-19
RU2012110324A (ru) 2013-10-10
KR101612988B1 (ko) 2016-04-15
SI2470202T1 (sl) 2014-02-28
CN103816530A (zh) 2014-05-28
US20180185460A1 (en) 2018-07-05
US9186395B2 (en) 2015-11-17
ES2564677T3 (es) 2016-03-28
KR20120103760A (ko) 2012-09-19
CY1114792T1 (el) 2016-12-14
DK2470202T3 (da) 2014-01-27
US20110052636A1 (en) 2011-03-03
US20160067319A1 (en) 2016-03-10
EP2708239A1 (en) 2014-03-19
AU2010289969A1 (en) 2012-03-22
US8147848B2 (en) 2012-04-03
US20140140981A1 (en) 2014-05-22
JP2015163654A (ja) 2015-09-10
EP2470202B1 (en) 2013-12-18
ES2446969T3 (es) 2014-03-11
CN103816530B (zh) 2016-12-07
JP6078108B2 (ja) 2017-02-08
JP2013503165A (ja) 2013-01-31
EP2708239B1 (en) 2015-12-09
DK2708239T3 (en) 2016-03-14
AU2010289969B2 (en) 2015-05-14
HK1171658A1 (en) 2013-04-05
JP5766699B2 (ja) 2015-08-19
US20130059789A1 (en) 2013-03-07
BR112012004246A2 (pt) 2016-04-05
AU2015213381B2 (en) 2017-05-25
US8617570B2 (en) 2013-12-31
WO2011028371A1 (en) 2011-03-10
US10420823B2 (en) 2019-09-24
AU2015213381A1 (en) 2015-09-03
US9907841B2 (en) 2018-03-06
PT2470202E (pt) 2014-02-24
US20120148563A1 (en) 2012-06-14
CN102802663A (zh) 2012-11-28
CA2772372C (en) 2016-07-12
US8329193B2 (en) 2012-12-11
HK1194292A1 (en) 2014-10-17
RU2568844C2 (ru) 2015-11-20
MX2012002378A (es) 2012-06-28
US20170020997A1 (en) 2017-01-26
PL2470202T3 (pl) 2014-05-30
IN2012DN02210A (enExample) 2015-08-21
US9457069B2 (en) 2016-10-04
CA2772372A1 (en) 2011-03-10
US8916177B2 (en) 2014-12-23
US20150064167A1 (en) 2015-03-05
EP2470202A1 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
IN2012DN02210A (enExample)
MX351448B (es) Enzimas de clostridium histolyticum y métodos para el uso de los mismos.
WO2012047733A3 (en) Treatment of acne by conditioned media
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
AU2010236286A8 (en) Modulation of inflammatory responses by Factor XI
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
SG10201804809RA (en) Clostridium difficile antibodies
MX2010004488A (es) Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
ECSP13013060A (es) Composiciones de nucleasa terapéuticas y métodos
WO2010138395A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
MX2010003371A (es) Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
EA201491418A1 (ru) Рекомбинантные микроорганизмы и способы их применения
AU2018256482A1 (en) Antibodies Against Clostridium Difficile
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
WO2010138393A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
TN2011000403A1 (en) Compositions and methods for extended therapy wiht aminopyridines
PH12016500136B1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
WO2010138387A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2010138392A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
PH12014500057A1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
MX2010007810A (es) Coposicion que contiene capsicum para tratar un trastorno de la piel.
HK1223632A1 (zh) 靶向的酶化合物及其用途
WO2010138389A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2010138384A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin